Tracking the results of drug safety and efficacy
Drug Updates
Information on new approvals and medication safety.
ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
Detailed screening and treatment recommendations based on current evidence, extensive literature review.
Medication Quick Guides Offer Infusion Staff a Streamlined Resource
The ACR/ARHP Medication Quick Guides offer easily accessable pharmaceutical information to rheumatologists.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.
Letter: RA Approval for IL-1Ra
Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK